EPA vs DHA: what the evidence shows
EPA and DHA are the two main omega-3 fatty acids in fish oil, but their evidence profiles differ. Triglyceride reduction has strong support (Grade A). Cardiovascular outcome evidence depends heavily on dose and patient population. Here is an honest breakdown of what each does and does not do, with third-party-certified options listed.
Evidence grade: well established in clinical research. This reflects the weight of current clinical literature; not medical advice.
Key Takeaways
- Third-party certification (NSF, USP, Informed Sport) means a public registry lists the product; we track those registries. We do not run the tests.
- Omega-3 (Fish Oil) has Grade A evidence for triglycerides: well established in clinical research.
- We found 23 certified Omega-3 (Fish Oil) products in public registries at time of review.
- Affiliate links appear only for products with an active certification listing. Grade and ranking cannot be purchased.
- Check the certification registry link on each product; listings can be removed when a cert lapses.
Evidence by use
Only certified products
Third-party certified Omega-3 (Fish Oil) products
Every product below is listed in a public third-party certification registry. We observe the registry; we do not run the tests.
Expert stacks
What researchers and practitioners say
Each expert's stated dose and rationale, linked to their own words. Attribution only; no endorsement implied.
EPA reduces inflammatory cytokines that divert tryptophan away from serotonin synthesis; cites a double-blind study finding 1,000 mg/day EPA equivalent to 20 mg fluoxetine for depressive symptoms, with synergistic effect when combined; personally states: 'I personally take 1000 milligrams of EPA per day... I notice a pretty substantial positive effect'
www.hubermanlab.com ↗States this is a superior product; had independent toxicology analytics conducted to confirm absence of lead, arsenic, mercury, and other contaminants; presents as part of his documented personal supplement stack
peterattiamd.com ↗Emphasizes Omega-3 Index as the relevant biomarker; cites evidence that >= 8% Omega-3 Index is associated with approximately 5 years greater life expectancy vs <= 4%; frames mechanism as resolution of inflammation through specialized pro-resolving mediators (SPMs); recommends testing Omega-3 Index rather than assuming a fixed dose
www.foundmyfitness.com ↗Uses algae-sourced omega-3 to avoid ocean contaminants and fish; emphasizes brain health (DHA as structural brain fat), heart health (blood pressure, vascular function, cholesterol support), and joint/inflammatory function; lower dose vs Attia/Patrick consistent with systematic risk/benefit optimization approach
blueprint.bryanjohnson.com ↗Recommends the lower end of the dose range, citing AHA guidance (250-500 mg/day) and concern about dose-dependent atrial fibrillation risk at >1,500 mg/day in high-CV-risk populations; notes VITAL (840 mg/day) did not show an AF risk signal and explicitly avoids megadosing
drstanfield.com ↗Sources
- Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA (2015) observational
- Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety (2015) observational
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (2019) rct
- Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (2019) rct
- Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) review
- Omega-3 Fatty Acid Dietary Supplements Consumed During Pregnancy and Lactation and Child Neurodevelopment: A Systematic Review (2021) review
- A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery (2019) rct
- Omega 3 fatty acid for the prevention of cognitive decline and dementia (2012) review